Business context and reporting period
This is Point Capital, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2019—not a Silo Pharma filing. The company had shifted from a business development company to developing and selling NFID apparel and footwear. It reported no revenue from the new business plan during the quarter.
Financial performance and position
| Metric | Q1 2019 | Q1 2018 / comparison |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $174,565 | $134,855 |
| Operating loss | $(174,565) | $(134,855) |
| Other income, net | $51,042 | $152,404 |
| Net income (loss) | $(123,523) | $17,549 |
| Basic and diluted loss per share | $(0.01) | $0.00 |
| Cash used in operating activities | $149,524 | Cash provided of $191,677 |
At March 31, cash and cash equivalents were $177,346, current assets $521,414, and current liabilities $58,185; working capital was $463,229. Total assets were $750,854. Stockholders’ equity was $292,669, alongside $400,000 of redeemable Series A preferred stock. Current liabilities included a $12,535 insurance-finance loan; the filing reports no other conventional debt balance.
No gross margin is reported because the company had no revenue. Operating expenses rose 29.4%, principally as professional fees increased to $128,102, including NFID marketing and advisory costs. The net result worsened by $141,072, as the prior-year period included a $234,251 realized investment gain; Q1 2019 instead recorded a $48,493 unrealized investment gain.
Material changes and notable items
- Cash declined $159,333 during the quarter, including $149,524 of operating cash use and $9,809 of insurance-loan repayment. Working capital declined from $578,002 at December 31, 2018.
- The company held $264,021 of fair-value equity securities, all in one issuer, Ipsidy Inc. (IDTY), representing 35.2% of total assets. Management said it planned to sell the shares and use proceeds for working capital, NFID development, or acquisitions.
- Net notes receivable were $200,000: this includes a secured $200,000 note bearing 6% interest, due September 2020, and a separate $50,000 note that was fully reserved after default.
- The company issued 25,000 shares to an NFID marketing consultant during the quarter and recorded $8,750 of stock-based professional fees. The agreement provides for a total of 100,000 shares in quarterly tranches and cash payments.
- Prior-year comparisons require care: the company changed from investment-company to commercial-company accounting effective September 29, 2018, and reclassified certain 2018 presentation items.
Outlook, risks, and controls
Management expected NFID.com apparel to launch in Q2 2019 and begin generating revenue, but provided no quantified revenue or earnings guidance. The stated strategy centers on direct-to-consumer sales, digital marketing, influencers, and limited product releases.
The filing says existing cash would not meet working-capital needs for at least 12 months and identifies substantial doubt about the company’s ability to continue as a going concern. Management was seeking additional debt or equity financing, had no financing agreements in place, and warned it might curtail operations if funding could not be raised. The financial statements contain no adjustments that might be required if the company cannot continue as a going concern.
Other key risks include dependence on a single investment for a significant portion of assets; the possibility that its value or sale proceeds differ from the reported fair value; collectability of notes receivable; potential redemption rights attached to preferred stock upon specified triggering events; and the lack of revenue from the new business. Management concluded disclosure controls were not effective, citing insufficient segregation of duties and inadequate system and manual controls; no material control changes occurred during the quarter. The filing reports no pending material legal proceedings and no off-balance-sheet arrangements.
Important facts for investors to verify
- Confirm the issuer identity: the supplied filing is for Point Capital, Inc., not Silo Pharma, Inc.
- Check whether NFID launched as expected and whether it generated sales after the quarter; the filing provides no actual Q2 outcome.
- Verify subsequent financing, cash runway, and any changes to the going-concern assessment.
- Review IDTY’s subsequent market value and whether the shares were sold, including actual proceeds available to fund operations.
- Confirm collection status and credit support for the secured $200,000 note and the defaulted, reserved $50,000 note.
- Resolve share-count presentation differences: the filing gives 23,442,450 shares outstanding as of May 14, 2019, while the statements of changes in equity show 23,442,540 at March 31 and the balance sheet shows 23,442,450.